Dr. Orme is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Division of Medical Oncology
200 1st St SW
Rochester, MN 55905Phone+1 507-255-5123
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 2016 - 2019
University of Texas Southwestern Medical SchoolClass of 2016
Certifications & Licensure
MN State Medical License 2017 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Young Investigator Award Prostate Cancer Foundation, 2022
Clinical Trials
- Metabolite Levels in Ovarian Cancer Patients Receiving Maintenance PARP Inhibitors Start of enrollment: 2021 Apr 01
Publications & Presentations
PubMed
- 20 citationsAn acetyl-histone vulnerability in PI3K/AKT inhibition-resistant cancers is targetable by both BET and HDAC inhibitors.Di Wu, Yuqian Yan, Ting Wei, Zhenqing Ye, Yu-Tian Xiao
Cell Reports. 2021-02-16 - 11 citationsEvaluation of PD-L1 and B7-H3 expression as a predictor of response to adjuvant chemotherapy in bladder cancer.Ahmed M Mahmoud, Igor Frank, Jacob J Orme, Roxane R Lavoie, Prabin Thapa
BMC Urology. 2022-06-24 - 2 citationsSalivary toxicity from PSMA-targeted radiopharmaceuticals: What we have learned and where we are going.Miguel Muniz, Charles L Loprinzi, Jacob J Orme, Regina M Koch, Ahmed M Mahmoud
Cancer Treatment Reviews. 2024-06-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
